respiratory:beta2_agonists:saba
Short-Acting β2 Agonists (SABA)
respiratory bronchodilator beta2_agonist saba
Short-acting β2 agonists are rapid bronchodilators used for immediate relief of bronchospasm.
They are the primary rescue medications in obstructive lung disease.
SABA = symptom relief They do NOT control inflammation
Drugs in Class
Mechanism of Action
Receptor
- β2 adrenergic receptor activation
Cellular Effect
- ↑ cAMP
- Smooth muscle relaxation
Physiologic Effects
- Bronchodilation
- ↓ airway resistance
- ↓ mast cell mediator release
- ↑ mucociliary clearance
- Intracellular potassium shift
Net effect:
- Rapid airway opening
Clinical Role
Primary uses:
- Acute asthma symptoms
- Exercise-induced bronchospasm
- COPD rescue therapy
Also used for:
- Hyperkalemia (temporary intracellular shift)
SABA should always be paired with controller therapy in persistent asthma:
Dosing Concept
| Situation | Meaning |
|---|---|
| Rare use | Controlled disease |
| >2 days/week | Inadequate control |
| Daily use | Needs escalation |
Frequent rescue inhaler use is a marker of worsening airway inflammation — not a need for more bronchodilator.
Adverse Effects
| Effect | Mechanism |
|---|---|
| Tremor | Skeletal muscle β2 stimulation |
| Tachycardia | β1 spillover |
| Hypokalemia | Intracellular potassium shift |
| Anxiety | Adrenergic stimulation |
Dose dependent.
Clinical Pearls
The rescue inhaler measures disease control.
More SABA = more inflammation
- First drug used in asthma exacerbation
- Spacer improves delivery significantly
- Nebulizer is easier, not stronger
- Overuse predicts hospitalization risk
Comparison Within β2 Class
Related
respiratory/beta2_agonists/saba.txt · Last modified: by andrew2393cns
